T. Rowe Price Associates’s Lipocine LPCN Stock Holding History

T. Rowe Price Associates’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,271	Closed	-$56K	–	2916
2023 Q1	$56K	Sell	10,271 -591	-5%	-$4.57K	﹤0.01%	2777
2022 Q4	$71K	Hold	10,862	–	–	﹤0.01%	2768
2022 Q3	$84K	Hold	10,862	–	–	﹤0.01%	2762
2022 Q2	$148K	Hold	10,862	–	–	﹤0.01%	2672
2022 Q1	$253K	Hold	10,862	–	–	﹤0.01%	2618
2021 Q4	$183K	Buy	10,862 +282	+3%	+$5.24K	﹤0.01%	2780
2021 Q3	$196K	Buy	10,580 +5,329	+101%	+$118K	﹤0.01%	2733
2021 Q2	$125K	Hold	5,251	–	–	﹤0.01%	2813
2021 Q1	$135K	Buy	+5,251	New	+$152K	﹤0.01%	2756
2020 Q4	–	Sell	-1,551	Closed	-$37K	–	2705
2020 Q3	$37K	Buy	+1,551	New	+$41.2K	﹤0.01%	2562

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates's LPCN Position: Q2 2023 in Review

T. Rowe Price Associates sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 10,271 shares — an estimated $56K sold.

T. Rowe Price Associates first reported a position in LPCN in Q3 2020 and held it in 10 quarters. The position peaked at $253K in Q1 2022. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

T. Rowe Price Associates reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 10,271 Lipocine shares in Q2 2023, an estimated $56K.
T. Rowe Price Associates first reported a position in Lipocine in Q3 2020 and held it in 10 quarters.
T. Rowe Price Associates's Lipocine position peaked at $253K in Q1 2022.
24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.